Endocrine and Metabolic Disease Clinical Development Expertise

Overcoming complexities to bring more metabolic disease treatments to market successfully

Metabolic diseases are a rising therapy area focus for clinical research due to the high demand for novel therapies that are challenged with proving safety and efficacy. The development process is complicated and full of unknowns, and even the best metabolic therapeutic might not make it to the patients that need it, not because it does not work but because the design, data collection, and analysis were not done right. 

At Veristat, we have assembled an extraordinary team of scientific-minded experts who have mastered the complexities of running metabolic disease trials.   Our team has supported 300+ projects for endocrine/metabolic disorder treatments and the preparation of 30+ marketing applications - 60% of which have been approved or authorized so far! 

Success with Lifestyle, Genetic, and Rare Metabolic Therapies

We strive to advance your novel metabolic therapies from Phase I-III clinical development to market with confidence.  

Our experienced teams are poised to plan and implement these efforts quickly, providing:     
Proven Expertise for Success
Veristat_icon_endocrinology-metabolic-216

300+

Endocrine/Metabolic Projects
Veristat_icon_rare-disease-216

80%

are for Rare/Ultra-Rare Disorders
Veristat_icon_gene therapy

> 70%

are Genetic Disorders

Explore Our Endocrine Experience

Get the right strategic consultation, clinical program implentation, regulatory approval registration, and post-marketing support for endocrine and metabolic therapies based upon our extensive first-hand knowlege.   

Breadth of Therapy Indications
   Achondropasia    Gaucher Disease    Lipodystrophy
   Adrenoleukodystrophy (ALD) and Thalassemia    Generalized Lipodystrophy    Lysosomal Acid Lipase (LAL) Deficiency
   Alpha-mannosidosis (AM)    Gout (Hyperuricemia)    Maroteaux-Lamy Syndrome
   Anorexia    Growth Hormone Deficiencies/Abnormalities    Molybdenum Cofactor Deficiency
   Bardet-Biedl Syndrome and Alstrom Syndrome    Hereditary ATTR (hATTR) Amyloidosis    Mucopolysaccharidosis type IIIB
   Cerebral Adrenoleukodystrophy    Homocystinuria    Multiple Lysosomal Storage Disorders
   Chronic Pancreatitis    Homozygous Familial Hypercholesterolemia (HoFH)    Non-Alcoholic Steatohepatitis (NASH)
   Congenital Adrenal Hyperplasia    Hypercholesterolemia    Obesity
   Diabetes    Hyperoxaluria    Pharmacodynamic Markers
   Dyslipidemia    Hypertriglyceridemia    POMC deficiency
   Fabry Disease    Hypoleptinemic Dysmetabolic Disorder    Pompe Disease
   Familial Amyloid Polyneuropathy    Hypoparathyroidism    Pyruviate Kinase Deficiency
   Familial Chylomicronemia Syndrome (FCS)    Immunoglobulin A (IgA) Nephropathy    Vasomotor symptoms (VMS)

 

Learn More with These Resources

Newsletter

Is Your Trial Stuck?

Your teams have worked hard to meet your NDA timeline and complete your submission to the FDA only to receive a Refuse to File letter. In response, we stepped in to perform ...

Read

Case Study

Preparing Data for the Marketing Authorization Application ...

Read the case study to learn how we helped a biotech prepare the MAA submission for a recently acquired product. Our creative approach included utilizing one DB for three ...

Download

Conference Presentation

Turning Sponsor/CRO Relationships into Partnerships for ...

Get the presentation that was given at the Evolution Summit Fall 2019. Veristat and thier client Ascendis Pharma share thier thoughts on how to truly work as a ...

Download
Request A Proposal
  • Privacy Policy
  • ©2006 - 2022 Veristat, LLC. All rights reserved. Veristat is a trademark of Veristat, LLC. All other trademarks are the property of their respective owners.